The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients
Tóm tắt
Nitrogen-containing bisphosphonates (N-BPs) inhibit osteoclast-mediated bone resorption and are widely used for tumor-associated osteolysis. The mechanism of action of these drugs has not been completely clarified, but it has been observed that N-BPs may inhibit squalene synthase or farnesyl pyrophosphate synthase. Zoledronic acid (ZA) represents a novel N-BP which also has antitumor activity. To explore the effects of ZA on serum lipids, we studied 26 patients with smoldering myeloma at diagnosis. Sixteen patients were treated with ZA (4 mg) at baseline and at months 1, 2, 4, and 6. The remaining 10 served as controls. In all subjects, total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and C-terminal telopeptide of type I collagen (CTX) were measured at baseline and after 1, 3, and 6 months. In treated patients, we observed a progressive and significant reduction of TC, with a maximum decrease of 13% at 6 months. Moreover LDL-C decreased by 21% at 6 months, while no significant difference was appreciated in HDL-C and TGs. Also, the indexes of cardiovascular risk improved after ZA administration: TC/HDL-C ratio progressively decreased by 17% and HDL-C/LDL-C ratio increased by 36%, showing an effect that appears to be cumulative. In conclusion, ZA given intravenously at high doses in patients with smoldering myeloma seems to be able to modify the lipid profile with an improvement of atherosclerotic risk index.
Tài liệu tham khảo
Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657–1663
Lehenkari PP, Kellinsalmi M, Napankangas JP et al (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a non-hydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255–1262
Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425–430
Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643–2658
Russel RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanism of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int, Jan 24 [Epub ahead of print]
Luckman SP, Hughes De, Coxon FP et al (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res 13:581–589
Coxon FP, Helfrich MH, Van’t Hof R et al (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467–1476
Croucher PI, De Hendrik R, Perry MJ et al (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18:482–492
Derenne S, Amiot M, Barille S et al (1999) Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14:2048–2056
Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G (2003) Human T cell receptor cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197:163–168
Fiore F, Castella B, Nuschak B et al (2007) Enhanced ability of dendritic cells to stimulate innate and adaptative immunity on short-term incubation with zoledronic acid. Blood 110:921–927
Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E (2000) Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 15:599–604
Montagnani A, Gonnelli S, Cepollaro C, Campagna MS, Franci MB, Pacini S, Gennari C (2003) Changes in serum HDL and LDL cholesterol in patients with Paget’s bone disease treated with pamidronate. Bone 32:15–19
Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaun C, Faye JC, Seronie-Vivien S (2006) Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6:60
Martini G, Gozzetti A, Salvadori S, Gennari L, Avanzati A, Franci B, Campagna M, Nuti R, Lauria F (2006) Zoledronic acid increases serum osteoprotegerin in early stage multiple myeloma. Haematol 91:1720–1721
Friedwald WT, Levy RI, Fredrickson DS (1972) Estimation of serum low density lipoprotein cholesterol without use of the preparative ultracentrifuge. Clin Chem 18:499–502
Nuti R, Martini G, Valenti R et al (2004) Vitamin D status and bone turnover in women with acute hip fracture. Clin Orthop Relat Res 422:208–213
Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVEs study). Am J Cardiol 81:582–587
Jones P, Davidson MH, Stein EA et al (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across dose (STELLAR trial). Am J Cardiol 92:152–160
Buhaescu I, Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Bioch 40:575–584
Ylitalo R (2002) Bisphosphonates and atherosclerosis. Gen Pharmacol 35:287–296
Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M (2005) Bisphosphonates and atherosclerosis: why? Lupus 14:773–779
Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 70:1537–1538
Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822
Cummings SR, Schwartz AV, Black DM (2007) Alendronate and atrial fibrillation [letter]. N Engl J Med 356:1895–1896
Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809
Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gammadelta T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101–111
Aviles RJ, Martin DO, Apperson-Hansen C et al (2003) Inflammation as a risk factor for atrial fibrillation. Circulation 108:3006–3010
Van Wagoner DR, Nerbonne JM (2000) Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol 32:1101–1117